All Oncology News

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab was found to significantly improve event-free survival over neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk, early-stage triple-negative breast cancer.

Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Delays between biopsy and the start of induction chemotherapy, induction chemotherapy and surgery, and surgery and consolidation chemotherapy were associated with a poor prognosis in patients with localized Ewing sarcoma.

The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non–small cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities.

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.

Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations.

The FDA has lifted a partial clinical hold that was placed on a first-in-human, phase 1b trial evaluating RVU120 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.

Zev A. Wainberg, MD, and Jaffer A. Ajani, MD, discuss how to best utilize information provided to inform treatment decisions, treatment approaches for patients with newly diagnosed RAS wild-type mCRC, and factors that affect influence selecting a 2- vs 3-drug chemotherapy regimen.

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

Prithviraj Bose, MD, discusses data with pelabresib from the MANIFEST trial and future research directions for BET inhibition in patients with myelofibrosis.

The combination of eprenetapopt and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Richard Gorlick, MD, expands on the process of identifying these novel targets in osteosarcoma and the clinical implications of this research for these patients.

The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme.

Sarabdeep “Sabi” Singh has been named executive vice president and chief operating officer of Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.

Naveen Pemmaraju, MD, discusses approaches to adequately manage symptoms experienced by patients with myelofibrosis, challenges faced with defining disease progression, and strategies for when to initiate or delay treatment.

The median progression-free survival benefit experienced by patients with metastatic breast cancer who were HER2 positive at initial diagnosis and who were receiving standard HER2-directed therapies proved to be more favorable than what was reported in those who were HER2 negative and switched to HER2 positive status.

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.